

Schizandrin A Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Schizandrin A

Catalog No.: CFN99922

Cas No.: 61281-38-7

Purity: >=98%

M.F: C₂₄H₃₂O₆

M.W: 416.51

Physical Description: Powder

Synonyms:Dibenzo(a,c)cyclooctene,5,6,7,8-tetrahydro-6,7-dimethyl-1,2,3,10,11,12-hexa met;R(+) Dedoxyschisandrin A;R(+) Schizandrin A; WUWEIZISU A.

[Intended Use]

- 1. Reference standards;
- 2. Pharmacological research;
- 3. Synthetic precursor compounds;
- 4. Intermediates & Fine Chemicals;
- 5. Others.

[Source]

The seeds of Schisandra chinensis (Turcz.) Baill.

[Biological Activity or Inhibitors]

Schizandrin A has neuroprotective effect on oxygen and glucose deprivation/

Reperfusion-induced cell injury in primary culture of rat cortical neurons, it may act as a

candidate therapeutic target drug used for brain ischemia and related diseases.[1]

Schizandrin A has the reversal effect of drug resistance in different mechanisms of the two

cell lines of K562/ADR and HL60/ADR, it increases the concentration of the drug resistant

cells mainly by inhibiting the function and expression of P-gp,MRP1 protein and reducing

mdr1,mrp1 gene expression and GSH content,and then it enhances the sensitivity and

reversal effects of resistant cell lines.[2]

Schizandrin A can exert anti-inflammatory and neuroprotective effects by alleviating

microglia-mediated neuroinflammation injury through inhibiting the TRAF6-IKKβ-NF-κB

and Jak2-Stat3 signaling pathways. [3]

Schizandrin A is able to inhibit CYP3A activity in rat liver microsomes, the inhibition is

mixed type, non-competitive and anti-competitive inhibition. [4]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[5]

Mobile phase: Acetonitrile-0.1%Phosphoric acid H2O, gradient elution;

Flow rate: 1.0 ml/min;

Column temperature: 40 °C;

The wave length of determination: 254 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

[1] Wang C P, Li G C, Shi Y W, et al. J. Physiol. Biochem., 2014, 70(3):735-47.

- [2] Qin X Q, Liang Y G, Gao H Z, et al. Chinese Pharmacological Bulletin, 2011, 27(3): 329-34.
- [3] Song F J, Zeng K W, Liao L X,et al. Plos One, 2016, 11(2): e0149991.
- [4] Su M W, Li W L, Liu H M, et al. Chinese Journal of Clinical Pharmacology & Therapeutics, 2009, 14(11):1275-80.
- [5] He H Y, Zhang Y, Liu H M. J. Pharmaceut. Res., 2015(11):642-4.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,

Wuhan Economic and Technological Development Zone,

Wuhan, Hubei 430056,

China

Email: info@chemfaces.com

Tel: +86-27-84237783 **Fax:** +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com